Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Key facts

Sponsor

National Cancer Institute (NCI)

Principal Investigator

Sikander Ailawadhi

SWOG Cancer Research Network

Intervention

Biospecimen Collection(procedure)

Enrollment

92 target

Eligibility

18 years · All sexes

Timeline

2022 – 2028

Study locations (30)

• Banner University Medical Center - Tucson, Tucson, Arizona, United States
• University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
• UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States
• UM Sylvester Comprehensive Cancer Center at Coral Springs, Coral Springs, Florida, United States
• UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States
• UM Sylvester Comprehensive Cancer Center at Doral, Doral, Florida, United States
• UM Sylvester Comprehensive Cancer Center at Hollywood, Hollywood, Florida, United States
• Mayo Clinic in Florida, Jacksonville, Florida, United States
• University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
• UM Sylvester Comprehensive Cancer Center at Kendall, Miami, Florida, United States
• University of Miami Sylvester Comprehensive Cancer Center at Sole Mia, North Miami, Florida, United States
• UM Sylvester Comprehensive Cancer Center at Plantation, Plantation, Florida, United States
• Centralia Oncology Clinic, Centralia, Illinois, United States
• Carle at The Riverfront, Danville, Illinois, United States
• Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for B-cell non-Hodgkin lymphoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07133997
  Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia
  City of Hope Medical Center
• RECRUITINGPHASE1NCT07361224
  Investigator Initiated Study to Assess the Safety of Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive Large B Cell Lymphoma at Lymphodepletion.
  Tel-Aviv Sourasky Medical Center
• RECRUITINGPHASE2NCT07523737
  Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma
  Beijing Tongren Hospital
• RECRUITINGPHASE1, PHASE2NCT07283679
  Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
  M.D. Anderson Cancer Center
• RECRUITINGPHASE1, PHASE2NCT07135466
  A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies
  Sheba Medical Center
• ACTIVE NOT RECRUITINGPHASE2NCT07480850
  Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma
  Cancer Institute and Hospital, Chinese Academy of Medical Sciences
• ACTIVE NOT RECRUITINGNCT07480837
  Dynamic Monitoring of Plasma ctDNA for Prognostic Assessment in Patients With B-Cell Non-Hodgkin Lymphoma
  Cancer Institute and Hospital, Chinese Academy of Medical Sciences
• RECRUITINGEARLY PHASE1NCT07376642
  A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
  Suzhou Immunofoco Biotechnology Co., Ltd

See all trials for B-cell non-Hodgkin lymphoma →